What We Treat

The Cancer Predisposition Program at the Aflac Cancer and Blood Disorders Center of Children's treats children under the age of 18 who are at risk for developing cancer due to a cancer predisposition syndrome, a family history of cancer or a diagnosis of a rare type of cancer.

What is a cancer predisposition syndrome?

A cancer predisposition syndrome is when an individual is born with a genetic mutation (or change) that increases his or her baseline risk for developing cancer. Estimates say that 10 percent of all pediatric cancers are caused by a cancer predisposition syndrome.

Pediatric cancer syndromes:

  • Li-Fraumeni syndrome
  • Leukemia and lymphoma predisposition syndromes
  • Bloom syndrome
  • DICER1 syndrome
  • Familial adenomatous polyposis
  • Von Hippel Lindau disease
  • Constitutional mismatch repair deficiency syndrome

Types of tumors or malignancies that may suggest a pediatric cancer predisposition syndrome:

  • Choroid plexus carcinoma
  • Adrenocortical carcinoma
  • Hepatoblastoma
  • Osteosarcoma
  • Rhabdomyosarcoma
  • Thyroid carcinoma (medullary)
  • Pleuropulmonary blastoma
  • Renal cell carcinoma
  • Leukemia and lymphoma

Services We Offer

Our program offers:

  • Genetic counseling and risk assessments
  • Comprehensive medical evaluations by a pediatric oncologist
  • Genetic testing with pre and post-test counseling
  • Personalized tumor surveillance options
  • Research study enrollment (when appropriate)
  • Identification of clinical trials (when appropriate)

Our Unique Approach

As the only clinic of its kind in the state of Georgia and the Southeast, we provide a multidisciplinary approach, incorporating comprehensive, pediatric-focused genetic counseling and cutting edge genetic tools to ensure the highest level of care for each patient and their family.

Our highlights:

  • U.S. News & World Report ranks us among the top pediatric cancer programs in the country.
  • We are the largest pediatric cancer center in the Southeast.
  • In 2016, we ranked number one in the country for therapeutic clinical trial enrollment.

Meet the Team

Meet the Team